摘要
目的评价左西孟旦治疗慢性心力衰竭的临床疗效及安全性。方法选取慢性充血性心力衰竭患者72例,随机分为观察组和对照组,每组36例,观察组患者用左西孟旦治疗,对照组患者用多巴酚丁胺治疗,比较两组患者治疗总有效率,检测两组用药前、用药后24 h左室射血分数及血浆NT-proBNP水平的变化。结果观察组患者治疗总有效率高于对照组(P<0.05),观察组患者用药24 h后血浆NT-proBNP水平降低及左室射血分数明显高于对照组(P<0.05),两组药物不良反应比较差异有统计学意义(P<0.05)。结论左西孟旦治疗慢性心力衰竭较多巴酚丁胺有效且安全性好,值得临床推广。
Objective To evaluate the effect and safety of levosimendan on patients with chronic heart failure. Methods Seventy-two cases of patients with chronic congestive heart failure were selected and randomly divided into observation group and control group, 36 cases in each group. The observation group was treated with levosimendan, the control group was treated with dobutamine. The clinical efficacy rate of the two groups was compared, left ventricular ejection fraction and plasma NT - proBNP levels before and after 24 h were detected. Results The total clinical efficacy rate of observation group was higher than the control group （P〈0.05）, after 24 h plasma NT-proBNP levels and left ventrieular ejection fraction of the observation group were significantly higher than the control group （P〈0.05）, adverse drug reactions between the two groups was statistically significant （/9〈0.05）. Conclusion Levosimendan has a better efficacy than dobutamine in the treatment of chronic heart failure, which is worth of clinical promotion.
出处
《临床医学研究与实践》
2016年第19期95-96,共2页
Clinical Research and Practice
